Brought to you by 
NeurogesX closes Series C private placement
31 Jan 2006
Executive Summary
NeurogesX (neuropathic pain therapeutics) raised $35mm through the closing of its Series C venture round. New investor Global Life Science Ventures led the placement, and was joined by Diamond Capital Management (representing Dow Employees' Pension Plan and Union Carbide Employees' Pension Plan) and existing investors Alta Partners, Arch Venture Partners, Montreux Equity Partners, Walden International, the Teachers Insurance and Annuity Association, and the University of North Carolina.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeurogesX closes Series C private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice